A First in Human Study to Assess the Safety, Tolerability, and Pharmacokinetics of DGX-001
Status:
Not yet recruiting
Trial end date:
2022-11-10
Target enrollment:
Participant gender:
Summary
This is a phase 1, randomized, double-blind, placebo-controlled, SAD and MAD study in healthy
adult volunteers. DGX-001 is a peptide being investigated for the treatment of the major
depressive disorder. This study will examine the safety and tolerability of increasing doses
of DGX-001 and, in an exploratory way, potential moderators and functional markers of its
activity.